摘要
[目的]评价奥沙利铂(oxaliplatin,OXA)联合吉西他滨(gemcitabine,GEM)治疗对顺铂(DDP)及5-氟尿嘧啶(5-Fu)耐药的复发晚期鼻咽癌的疗效及不良反应。[方法]对DDP、5-Fu耐药的局部复发晚期鼻咽癌42例,随机分为A、B两组,分别采用动脉、静脉两种途径用药。[结果]A组PR15例,SD5例,PD1例,有效率(RR)为71.4%;B组PR8例,SD8例,PD5例,RR为38.1%,P=0.030。A组的1年生存率为95.2%,B组的为66.7%,P=0.018。A组的中位生存时间为16个月,B组为14个月,P=0.013。A组的不良反应除外周感觉神经异常明显少于B组外,其它不良反应无差别。[结论]OXA联合GEM治疗对DDP、5-Fu耐药的复发晚期NPC有效,毒性反应可以耐受。经动脉用药较经静脉用药的有效率较高,外周感觉神经异常的发生率较低。
[Purpose]To evaluate the efficacy and toxicity of oxaliplatin （OXA） combined with gemcitabine（GEM） for the treatment of DDP/5-Fu resistant recurrent or advanced nasopharyngeal carcinoma （NPC）. [Methods] Forty-two patients with DDP/5-Fu resistant recurrent NPC undergoing OXA and GEM chemotherapy were divided randomly into 2 groups： group A （artery administered） and group B （venous administered）. [Results] There were 15 patients achieved partial remission （PR）, 5 patients achieved stable disease（SD）, one patient achieved progress disease（PD）, with response rate（RR） 71.4% in group A; and 8, PR; 8, SD, 5, PD; with RR 38.1% in group B（P=0.030）. The 1-year survival rate was 95.2% in group A and 66.7% in group B （P=0.018）. The median survival was 16 months in group A and 14 months in group B（P=0.013）. There was no significant difference between group A and group B in toxicity except the peripheral sensory neuropathy was markedly less in group A than that in group B. [Conclusions] OXA combined with GEM is effective far DDP/5-Fu resistant recurrent NPC with tolerable toxicity. There is higher response rate and less peripheral sensory neuropathy when the drugs were administered by artery than venous.
出处
《肿瘤学杂志》
CAS
2006年第5期409-411,共3页
Journal of Chinese Oncology
关键词
鼻咽肿瘤
药物疗法
奥沙利铂
吉西他滨
nasopharyngeal neoplasms
drug therapy
oxaliplatin
gemcitabine
